AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR
AMS:GLPG (4/25/2025, 11:42:09 AM)
23.34
+0.36 (+1.57%)
The current stock price of GLPG.AS is 23.34 EUR. In the past month the price decreased by -4.33%. In the past year, price decreased by -13.87%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.15 | 285.69B | ||
AMG.DE | AMGEN INC | 14.17 | 132.75B | ||
GIS.DE | GILEAD SCIENCES INC | 23.35 | 117.88B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1728.6 | 111.10B | ||
ARGX.BR | ARGENX SE | 349.93 | 32.48B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 25.22B | ||
IDP.DE | BIOGEN INC | 7.29 | 15.44B | ||
0QF.DE | MODERNA INC | N/A | 9.24B | ||
1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
BIO.DE | BIOTEST AG | 24.8 | 1.68B | ||
BIO3.DE | BIOTEST AG-VORZUGSAKTIEN | 17.54 | 1.19B | ||
AZT.OL | ARCTICZYMES TECHNOLOGIES ASA | 124.29 | 888.62M |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 683
Company Website: https://www.glpg.com/
Investor Relations: https://www.glpg.com/investor-center
Phone: 3215342900
The current stock price of GLPG.AS is 23.34 EUR. The price increased by 1.57% in the last trading session.
The exchange symbol of GALAPAGOS NV is GLPG and it is listed on the Euronext Amsterdam exchange.
GLPG.AS stock is listed on the Euronext Amsterdam exchange.
19 analysts have analysed GLPG.AS and the average price target is 30.95 EUR. This implies a price increase of 32.62% is expected in the next year compared to the current price of 23.34. Check the GALAPAGOS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.54B EUR. This makes GLPG.AS a Small Cap stock.
GALAPAGOS NV (GLPG.AS) currently has 683 employees.
GALAPAGOS NV (GLPG.AS) has a support level at 22.85 and a resistance level at 23.23. Check the full technical report for a detailed analysis of GLPG.AS support and resistance levels.
The Revenue of GALAPAGOS NV (GLPG.AS) is expected to decline by -6.96% in the next year. Check the estimates tab for more information on the GLPG.AS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLPG.AS does not pay a dividend.
GALAPAGOS NV (GLPG.AS) will report earnings on 2025-04-23, after the market close.
GALAPAGOS NV (GLPG.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.43).
ChartMill assigns a technical rating of 1 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS is a bad performer in the overall market: 65.85% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS. GLPG.AS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -2.43. The EPS decreased by -157.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 25.35% | ||
ROA | 1.79% | ||
ROE | 2.56% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 49% to GLPG.AS. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -198.38% and a revenue growth -6.96% for GLPG.AS